Navigation Links
Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc.
Date:12/4/2008

SAN JUAN, Puerto Rico, Dec. 4 /PRNewswire-FirstCall/ -- Triple-S Management Corporation (NYSE: GTS) today announced that it has signed a non- binding letter of intent to acquire certain managed care assets of La Cruz Azul de Puerto Rico, Inc. In addition, the Company requested Blue Cross Blue Shield Association to transfer the licensing rights to the Blue Cross brand in Puerto Rico and the Blue Cross and Blue Shield brands in the US Virgin Islands to the Company and Triple-S, Inc., its managed care subsidiary. Terms of the proposed acquisition are not yet finalized and are subject to change. The completion of the transaction is subject to a number of customary conditions including final due diligence, approvals from the Insurance Commissioner of Puerto Rico and the Blue Cross Blue Shield Association, and completion of the negotiation of definitive documentation. The Company intends to fund the acquisition with cash and expects to complete the acquisition by the end of the first quarter of 2009.

La Cruz Azul de Puerto Rico is an independent licensee of the Blue Cross Blue Shield Association that offers medical, prescription drug, and dental coverage to individuals and employer groups of all sizes. Its annualized premiums for the year ended December 31, 2007 was approximately $88 million. Established in 1943, La Cruz Azul de Puerto Rico is a wholly-owned subsidiary of Independence Blue Cross, also an independent licensee of the Blue Cross Blue Shield Association.

Ramon M. Ruiz-Comas, President and Chief Executive Officer of Triple-S Management Corporation, stated, "This acquisition is an example of our disciplined strategy to extend our market leadership while creating long-term value for our shareholders. The acquisition of certain of La Cruz Azul's managed care assets represents an opportunity that allows us to consol
'/>"/>

SOURCE Triple-S Management Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Triple-S Management Corporation Announces Full Exercise of Underwriters Over-Allotment Option
2. Triple-S Management Corporation to Present at UBS Global Healthcare Conference
3. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
4. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
5. Triple-S Management Corporation Reports First Quarter 2008 Results; Cites Growth Resulting From Strong Market Position
6. Triple-S Management Corporation Schedules Second-Quarter Earnings Release and Webcast
7. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
8. Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference
9. Case Management Cost-Effective Way to Cut Heart Risks
10. S.C. BlueCross to Integrate Care Management with Personal Health Record in Real Time
11. Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)... November is Alzheimer,s Awa...eimer Report declares that more than 35 million pe...nior Living Communities , an industry innovator wi...Alzheimer,s/memory care communities in Wisconsin a...o care for people with Alzheimer,s. , ...
(Date:11/10/2009)...TLANTA Emory University Rollins School of Public ... of topics at the American Public Health Associati...tudy that examined compliance with national recomm...nts within 10 minutes of their arrival to the Emer...h research findings from Emory scientists are high...
(Date:11/9/2009)..., Campaign Backed by USDA Secretary Vilsack, Gov..., BOSTON, Nov. 9 In a ...an James P. McGovern (D-Worcester) called for all ... helping hungry patients in their care. ,, "Wi...re," said McGovern at today,s press conference at ...
(Date:11/9/2009)..., SHENZHEN, China, Nov. 9 /PRNewswire-Asia-Fi...(NYSE: MR ), a leading developer, manufacturer an... today its selected unaudited,financial results fo...r 30,2009. , , Highlights for Operations as o... revenues were $151.1 million, an increase of, ...
(Date:11/9/2009)..., SBA Provision, Antitrust Language, Federal Tra...Senate ,, WASHINGTON, Nov. 9 /PRNewswire-USNew...le Health Care for America Act (H.R. 3962) allowin... by health insurance exchanges is positive, but ot...ccording to the National Association of Profession...
Breaking Medicine News(10 mins):Health News:Top 10 Tips for Alzheimer's Caregivers 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 2Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 3
...Two carotid stenting,trials examining outcomes in ...e results that are comparable to guidelines establ...or patients treated with carotid artery,surgery. T...anscatheter Cardiovascular Therapeutics (TCT),scie...
...bar with innovative CM-X gives new meaning to diab...TO, Oct. 23 Heart Chocolate(TM) with CM-X(TM),rec...tion (ILS), is more,than just another so-called di...consumers are left feeling unsatisfied,because alt...
...to Provide Information and Product Acquisition, S... of,the recent tragedies caused by Community Acqui...ions, LLC, part of the Key Medical Group of,Compan...o combat and kill these superbugs. The website:, h...
...,s plasma, rare lung condition, study finds , TUES...ted by females may not be as dangerous as believed...e that would limit the use of plasma from female d...rtion of blood that,s separated from red blood cel...
...dies presented at the AACR-NCI-EORTC International...eutics demonstrate the flexibility of targeted the...and tested in human trials more quickly and safely...rs, both currently involved in solid tumor clinica...
...outhfield, MI October 23, 2007 The Juvenile Diab...itable funder of type 1 diabetes research, today a...Research Laboratories (HPRL) to support the compan...are thrilled to be partnering with Housey Pharmace...
Other Medicine News:Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 2Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 3Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 4Health News:Heart Chocolate(TM) With CM-X(TM) is Loved by Chocolate Connoisseurs and Diabetics Alike 2Health News:Heart Chocolate(TM) With CM-X(TM) is Loved by Chocolate Connoisseurs and Diabetics Alike 3Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 2Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 3Health News:Female Blood Donor Concern May Be Unfounded 2Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 2Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 3Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 4Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 5Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 6Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 7Health News:JDRF partners with Housey Pharmaceutical Research Laboratories 2
(Date:11/9/2009)...h., Nov. 9 Cardiac Sci...er in automated external defibrillator ( AED ) a...nounced revenue of $38.9 million for the third qua...evious guidance. The Company also recorded a charg... and a non-cash charge of $44.0 million to increas...
(Date:11/9/2009)...l., Nov. 9 Landauer, In... and environmental radiation monitoring services, ... in accordance with its long-term strategic priori...itions of Global Physics Solutions, Inc. (GPS) and..., President and CEO of Landauer. "These acquisitio...
(Date:11/9/2009)...v. 9 Keryx Biopharmaceut...company focused on the acquisition, development an...eutical products for the treatment of life-threate...(the "Company"), today announced its results for t...t September 30, 2009, the Company had cash, cash e...
Breaking Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 6Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 1Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 2Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 3Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 1Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 6Irvine Scientific and Selexis to Announce Results of Successful Collaboration 14427 1Irvine Scientific and Selexis to Announce Results of Successful Collaboration 14427 2
...w Aggrastat Study in American Heart Journal , ,WI...TSX:MPH;,Amex:MCU), a cardiovascular focused, biop...o-year, follow-up results from the,STRATEGY (Singl...Stent Versus Abciximab and Bare Metal Stent In Acu...the July edition of the Journal,of the American Co...
...n., July 11, 2007 /PRNewswire/ -- Phase 3 results,...l dabigatran,etexilate once daily, administered fo...parin, also administered for an average of 33,days...ll-cause,mortality after total hip replacement sur...sociated with dabigatran etexilate was,similar to ...
Other Medicine Technology:Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 3Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 4Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5
Vannas Capsulotomy scissors angled forward
Vannas Capsulotomy scissors straight
Gills-Vannas straight capsulotomy flat handle scissors
Vannas side angled capsulotomy round handle scissors
Medicine Products: